Sensei acquires Faeth for $133M, raises $200M, pivots to PIKTOR; solnerstotug deprioritized

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 6, 2025 · ~2 min read

Key Changes

• high

  Completed acquisition of Faeth Therapeutics in February 2026, recording $133M IPR&D charge and raising $200M concurrent financing. PIKTOR (multi-node PI3K/AKT/mTOR inhibitor) is now lead program with Phase 2 endometrial cancer data expected H2 2026 and Phase 1b/2 breast cancer interim data in 2027.

  MD&A: Faeth acquisition and PIKTOR program verify on EDGAR →
• high

  Solnerstotug deprioritized from lead program to wind-down status. Planned Phase 2 trial and data presentation milestones removed; company now only "completing the remaining portion" of Phase 1/2 trial with existing patients.

  MD&A: solnerstotug status verify on EDGAR →
• high

  Going-concern doubt persists but basis shifted: $202.8M cash (vs $34.3M prior year) deemed sufficient for operations through PIKTOR data readouts, but contingent cash settlement obligations on Series B Preferred Stock could exceed available cash if stockholders reject charter amendment.

  Risk Factors: going concern basis verify on EDGAR →